Clinical observation of Shenyan Kangfu Tablet combined with Benazepril in treatment of diabetic nephropathy
肾炎康复片联合贝那普利治疗糖尿病肾病临床观察

摘要

目的 重点观察肾炎康复片联合贝那普利在治疗糖尿病肾病中的疗效价值，期待能将所有研究成果应用至实践中去，为临床提供有价值的理论参考与实践依据。方法 所选样本均为笔者院内收治的糖尿病肾病患者，人数共计100例，实验开展期限为2022年11月至2023年11月之间，按照入院顺序的先后进行组间划分，将其中50例患者划为一组，命名为参照组，实施贝那普利治疗方案；另外55例患者划为一组，命名为研究组，实施贝那普利联合肾炎康复片治疗方案，而后对相关数据展开收集整理，利用统计学方法予以比对分析，比对范围涉及：临床疗效、肾功能指标、氧化应激指标、内皮功能、不良反应发生率。结果 组间相较，治疗方案相较，研究组患者在各项指标数值的体现上，均显优参照组（P＜0.05），存在可比价值，值得探讨。结论 在本次实验中，有针对性的对肾炎康复片联合贝那普利在糖尿病肾病治疗中的应用效果展开分析研讨，目的在于通过对比方式寻求一种切实可行的治疗方案，有效抑制糖尿病肾病患者病情进展，结局所得明确，肾炎康复片与贝那普利的联合应用，不仅能有效提高临床疗效，且极大降低了不良反应发生概率，其应用价值卓越，推广意义深远，值得采纳。

Abstract

Objective To observe the therapeutic value of Shenyan Kangfu tablets combined with Benazepril in the treatment of diabetic nephropathy, and look forward to applying all the research results to practice to provide valuable theoretical reference and practical basis for clinical practice.
Methods The selected samples were all diabetic nephropathy patients admitted to our hospital, with a total of 100 cases. The duration of the experiment was from November 2022 to November 2023. According to the order of admission, 50 patients were divided into one group, named the reference group, and the Benazepril treatment regimen was implemented. The other 55 patients were divided into one group, named as the study group, and the treatment regimen of Benazepril combined with nephritis rehabilitation tablets was implemented. Then, relevant data were collected and sorted, and statistical methods were used for comparison and analysis, including clinical efficacy, renal function indicators, oxidative stress indicators, endothelial function, and incidence of adverse reactions.
Results Compared between groups, compared with treatment plans, patients in the study group were significantly better than those in the reference group (P < 0.05) in the embodiment of various index values, which had comparable value and was worth exploring.
Conclusion   In this experiment, the application effect of Shenyan Kangfu tablet combined with benazepril in the treatment of diabetic nephropathy was analyzed and discussed in a targeted way, aiming to seek a feasible treatment plan through comparison to effectively inhibit the progression of diabetic nephropathy patients, and the outcome was clear. The combined application of Shenyan Kangfu tablet and Benazepril could not only effectively improve the clinical efficacy, but also improve the clinical efficacy. And greatly reduce the probability of adverse reactions, its application value is excellent, far-reaching promotion significance, worthy of adoption.